Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Mol Cell Proteomics ; 20: 100110, 2021.
Article in English | MEDLINE | ID: mdl-34129939

ABSTRACT

Knowledge about the peptide repertoire presented by human leukocyte antigens (HLA) holds the key to unlock target-specific cancer immunotherapies such as adoptive cell therapies or bispecific T cell engaging receptors. Therefore, comprehensive and accurate characterization of HLA peptidomes by mass spectrometry (immunopeptidomics) across tissues and disease states is essential. With growing numbers of immunopeptidomics datasets and the scope of peptide identification strategies reaching beyond the canonical proteome, the likelihood for erroneous peptide identification as well as false annotation of HLA-independent peptides as HLA ligands is increasing. Such "fake ligands" can lead to selection of nonexistent targets for immunotherapeutic development and need to be recognized as such as early as possible in the preclinical pipeline. Here we present computational and experimental methods that enable the identification of "fake ligands" that might be introduced at different steps of the immunopeptidomics workflow. The statistics presented herein allow discrimination of true HLA ligands from coisolated HLA-independent proteolytic fragments. In addition, we describe necessary steps to ensure system suitability of the chromatographic system. Furthermore, we illustrate an algorithm for detection of source fragmentation events that are introduced by electrospray ionization during mass spectrometry. For confirmation of peptide sequences, we present an experimental pipeline that enables high-throughput sequence verification through similarity of fragmentation pattern and coelution of synthetic isotope-labeled internal standards. Based on these methods, we show the overall high quality of existing datasets but point out limitations and pitfalls critical for individual peptides and how they can be uncovered in order to identify true ligands.


Subject(s)
HLA Antigens , Peptides , Humans , Ligands , Proteolysis , Proteome , Proteomics
2.
Proteomics ; 18(12): e1700284, 2018 06.
Article in English | MEDLINE | ID: mdl-29505699

ABSTRACT

Immunotherapy is revolutionizing cancer treatment and has shown success in particular for tumors with a high mutational load. These effects have been linked to neoantigens derived from patient-specific mutations. To expand efficacious immunotherapy approaches to the vast majority of tumor types and patient populations carrying only a few mutations and maybe not a single presented neoepitope, it is necessary to expand the target space to non-mutated cancer-associated antigens. Mass spectrometry enables the direct and unbiased discovery and selection of tumor-specific human leukocyte antigen (HLA) peptides that can be used to define targets for immunotherapy. Combining these targets into a warehouse allows for multi-target therapy and accelerated clinical application. For precise personalization aimed at optimally ensuring treatment efficacy and safety, it is necessary to assess the presence of the target on each individual patient's tumor. Here we show how LC-MS paired with gene expression data was used to define mRNA biomarkers currently being used as diagnostic test IMADETECT™ for patient inclusion and personalized target selection within two clinical trials (NCT02876510, NCT03247309). Thus, we present a way how to translate HLA peptide presentation into gene expression thresholds for companion diagnostics in immunotherapy considering the peptide-specific correlation to its encoding mRNA.


Subject(s)
Antigens, Neoplasm/metabolism , HLA Antigens/metabolism , Immunotherapy , Neoplasms/metabolism , Peptide Fragments/metabolism , Precision Medicine , Proteogenomics/methods , Antigen Presentation/immunology , Antigens, Neoplasm/analysis , Antigens, Neoplasm/immunology , Decision Making , Epitopes/immunology , Epitopes/metabolism , HLA Antigens/analysis , HLA Antigens/immunology , High-Throughput Nucleotide Sequencing , Humans , Mass Spectrometry/methods , Neoplasms/immunology , Peptide Fragments/analysis , Peptide Fragments/immunology , RNA, Messenger/analysis , RNA, Messenger/genetics , RNA, Messenger/immunology
3.
Blood ; 109(4): 1701-11, 2007 Feb 15.
Article in English | MEDLINE | ID: mdl-17008552

ABSTRACT

Inhibition of BCR-ABL tyrosine kinase with imatinib represents a major breakthrough in the treatment of patients with chronic myeloid leukemia (CML). However, resistance to imatinib develops frequently, particularly in late-stage disease. To identify new cellular BCR-ABL downstream targets, we analyzed differences in global protein expression in BCR-ABL-positive K562 cells treated with or without imatinib in vitro. Among the 19 proteins found to be differentially expressed, we detected the down-regulation of eukaryotic initiation factor 5A (eIF5A), a protein essential for cell proliferation. eIF5A represents the only known eukaryotic protein activated by posttranslational hypusination. Hypusination inhibitors (HIs) alone exerted an antiproliferative effect on BCR-ABL-positive and -negative leukemia cell lines in vitro. However, the synergistic dose-response relationship found for the combination of imatinib and HI was restricted to Bcr-Abl-positive cells. Furthermore, this synergistic effect was confirmed by cytotoxicity assays, cell-cycle analysis, and CFSE labeling of primary CD34+ CML cells. Specificity of this effect could be demonstrated by cotreatment of K562 cells with imatinib and siRNA against eIF5. In conclusion, through a comparative proteomics approach and further functional analysis, we identified the inhibition of eIF5A hypusination as a promising new approach for combination therapy in BCR-ABL-positive leukemias.


Subject(s)
Fusion Proteins, bcr-abl , Gene Expression Regulation, Leukemic , Leukemia/drug therapy , Lysine/analogs & derivatives , Peptide Initiation Factors/metabolism , RNA-Binding Proteins/metabolism , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Benzamides , Cell Proliferation/drug effects , Down-Regulation/genetics , Drug Delivery Systems , Drug Synergism , Humans , Imatinib Mesylate , K562 Cells , Leukemia/pathology , Lysine/antagonists & inhibitors , Lysine/metabolism , Peptide Initiation Factors/genetics , Piperazines/pharmacology , Protein Processing, Post-Translational , Proteomics/methods , Pyrimidines/pharmacology , RNA-Binding Proteins/genetics , Eukaryotic Translation Initiation Factor 5A
4.
Liver Int ; 26(7): 846-55, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16911468

ABSTRACT

BACKGROUND: Primary biliary cirrhosis (PBC) is characterized by the presence of antimitochondrial antibodies (AMA). Autoantibodies specific for the mitochondrial M4 antigen can be detected by a complement fixation test (CFT) but not by immunoblotting. The aim of this study was to elucidate the identity of the M4 antigen. PATIENTS AND METHODS: M4 proteins were purified by affinity chromatography using IgG fractions of PBC marker sera being CFT positive (n=5) or negative (n=5) and identified by Western blotting, silver staining and sequence analysis. Further, a cohort of 57 PBC patients was tested for the reactivity to M4 and pyruvate dehydrogenase complex (PDC). RESULTS: Two AMA patterns of the marker sera were visualized: CFT-positive sera were defined as PDC-E2(+)/E1(+) and the CFT-negative sera as PDC-E2(+)/E1(-). The major proteins in the M4 fraction could be related to the PDC-E1 subunits. A clear-cut association between anti-M4 reactivity in the CFT and the reactivity to both PDC subunits could also be documented in the cohort of 57 PBC patients showing anti-PDC-E1alpha and E1beta antibodies at a frequency of 74% and 67%. CONCLUSIONS: CFT reactivity against M4 antigens could be preferentially identified as a reaction against PDC-E1. As PDC-E1 subunits as compared with PDC-E2 lack lipoyl-binding sites, they probably have to be considered as an independent and important target.


Subject(s)
Autoantigens/immunology , Liver Cirrhosis, Biliary/immunology , Pyruvate Dehydrogenase (Lipoamide)/immunology , Aged , Aged, 80 and over , Animals , Autoantibodies/blood , Autoantibodies/immunology , Cohort Studies , Complement Fixation Tests , Female , Humans , Immunodominant Epitopes/immunology , Liver Cirrhosis, Biliary/blood , Male , Middle Aged , Mitochondria/immunology , Pyruvate Dehydrogenase Complex/immunology , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...